Most cancer-associated deaths occur due to metastasis, yet our understanding of metastasis
as an evolving, heterogeneous, systemic disease and of how to effectively treat it is still …

Breast cancer remains a leading cause of cancer-related mortality in women, reflecting
profound disease heterogeneity, metastasis, and therapeutic resistance. Over the last …

PURPOSE Patients with pretreated estrogen receptor (ER)–positive/human epidermal
growth factor receptor 2 (HER2)–negative advanced breast cancer have poor prognosis …

Advances in quantitative biomarker development have accelerated new forms of data-driven
insights for patients with cancer. However, most approaches are limited to a single mode of …

Despite recent therapeutic advances in cancer treatment, metastasis remains the principal
cause of cancer death. Recent work has uncovered the unique biology of metastasis …

Metastatic progression is the main cause of death in cancer patients, whereas the
underlying genomic mechanisms driving metastasis remain largely unknown. Here, we …

Novel antibody-drug conjugates against HER2 are showing high activity in HER2-negative
breast cancer (BC) with low HER2 expression (ie, 1+ or 2+ and lack of ERBB2 amplification) …

The majority of breast cancers express the estrogen receptor (ERα) and agents targeting this
pathway represent the main treatment modality. Endocrine therapy has proven successful in …

In metastatic hormone receptor-positive breast cancer, ESR1 mutations are a common
cause of acquired resistance to the backbone of therapy, estrogen deprivation by aromatase …

Estrogen receptor-positive (ER+) breast cancer is the most common breast cancer subtype.
Treatment of ER+ breast cancer comprises interventions that suppress estrogen production …